Header Logo

Nancy Reau

Concepts (260)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hepatitis C, Chronic
29
2021
40
9.380
Why?
Antiviral Agents
32
2021
69
8.150
Why?
Hepatitis C
20
2022
42
6.970
Why?
Liver Diseases
14
2022
31
6.140
Why?
Hepacivirus
23
2022
33
4.750
Why?
Liver Transplantation
9
2023
65
3.980
Why?
Pregnancy Complications
8
2022
48
3.970
Why?
Non-alcoholic Fatty Liver Disease
5
2024
5
2.200
Why?
Pregnancy Complications, Infectious
3
2020
10
1.930
Why?
Liver Cirrhosis
13
2024
42
1.880
Why?
Pregnancy
13
2022
310
1.750
Why?
Ribavirin
9
2016
10
1.710
Why?
Humans
71
2024
26260
1.670
Why?
Infectious Disease Transmission, Vertical
3
2020
7
1.550
Why?
Coinfection
4
2023
21
1.320
Why?
Sulfonamides
7
2020
37
1.250
Why?
Hepatitis B
5
2019
13
1.230
Why?
Interferon-alpha
5
2012
30
1.220
Why?
United States
19
2022
1989
1.210
Why?
Liver Neoplasms
4
2022
91
1.200
Why?
Polyethylene Glycols
5
2012
44
1.200
Why?
HIV Infections
4
2021
460
1.180
Why?
Carcinoma, Hepatocellular
3
2022
18
1.160
Why?
Female
37
2024
14516
1.120
Why?
Hepatitis, Autoimmune
2
2024
4
1.070
Why?
Societies, Medical
3
2022
146
0.990
Why?
Carbamates
9
2020
9
0.970
Why?
Quinoxalines
5
2020
6
0.920
Why?
Drug Therapy, Combination
13
2021
170
0.910
Why?
Hepatitis D
1
2023
1
0.880
Why?
Treatment Outcome
20
2021
3390
0.850
Why?
Gastroenterology
3
2017
6
0.810
Why?
Liver Diseases, Alcoholic
2
2021
39
0.790
Why?
Living Donors
1
2021
6
0.770
Why?
Prejudice
1
2021
31
0.760
Why?
Practice Patterns, Physicians'
1
2021
104
0.710
Why?
Thrombocytopenia
1
2020
21
0.710
Why?
Postoperative Hemorrhage
1
2020
21
0.710
Why?
Elective Surgical Procedures
1
2020
37
0.710
Why?
Benzimidazoles
3
2019
9
0.700
Why?
Patient Selection
1
2021
194
0.700
Why?
Kidney Transplantation
2
2018
120
0.680
Why?
Genotype
10
2017
335
0.680
Why?
Adult
21
2021
7447
0.650
Why?
Hypertension, Pregnancy-Induced
1
2019
2
0.650
Why?
Viral Load
5
2016
72
0.650
Why?
Sofosbuvir
6
2019
6
0.630
Why?
Heterocyclic Compounds, 4 or More Rings
6
2019
6
0.630
Why?
Obesity
1
2021
279
0.630
Why?
Algorithms
2
2020
363
0.630
Why?
Fear
1
2018
43
0.600
Why?
Liver
3
2022
123
0.600
Why?
Cholestasis, Intrahepatic
3
2019
4
0.600
Why?
Middle Aged
21
2021
8600
0.570
Why?
Drugs, Generic
1
2016
1
0.540
Why?
Cyclopropanes
5
2020
14
0.540
Why?
Antacids
1
2016
1
0.530
Why?
Proton Pump Inhibitors
1
2016
11
0.530
Why?
Pregnancy Complications, Neoplastic
1
2016
1
0.530
Why?
Sustained Virologic Response
6
2021
6
0.530
Why?
Virology
1
2015
2
0.520
Why?
Young Adult
9
2021
1886
0.480
Why?
Length of Stay
2
2016
304
0.480
Why?
Patient Readmission
1
2016
128
0.470
Why?
Liver Function Tests
3
2022
19
0.470
Why?
Male
23
2021
14124
0.450
Why?
Mass Screening
5
2021
166
0.450
Why?
Heart Failure
1
2016
171
0.450
Why?
Prevalence
3
2023
437
0.440
Why?
Risk Factors
6
2023
2265
0.440
Why?
Patient Reported Outcome Measures
6
2021
495
0.440
Why?
Preventive Health Services
1
2013
15
0.430
Why?
Prognosis
5
2022
758
0.430
Why?
Advisory Committees
1
2013
22
0.430
Why?
Periodicals as Topic
2
2023
35
0.430
Why?
Health Policy
1
2013
49
0.420
Why?
Retrospective Studies
9
2024
3366
0.410
Why?
Disease Management
2
2016
109
0.400
Why?
Hepatitis C Antibodies
2
2022
4
0.390
Why?
Proline
4
2019
10
0.370
Why?
Lactams, Macrocyclic
4
2019
5
0.370
Why?
Imidazoles
4
2020
55
0.360
Why?
RNA, Viral
4
2022
44
0.360
Why?
Recombinant Proteins
5
2012
200
0.360
Why?
Macrocyclic Compounds
4
2019
4
0.350
Why?
Pregnancy Outcome
2
2021
16
0.350
Why?
Drug Resistance, Viral
4
2017
14
0.340
Why?
Aged
14
2020
8764
0.330
Why?
Drug Administration Schedule
3
2018
156
0.310
Why?
Cost of Illness
2
2023
45
0.310
Why?
Bile Ducts, Intrahepatic
1
2008
3
0.300
Why?
Motivation
3
2023
92
0.300
Why?
Cohort Studies
6
2021
1838
0.290
Why?
Fatty Liver
2
2019
21
0.290
Why?
Anemia
1
2008
93
0.280
Why?
Medication Adherence
2
2019
68
0.280
Why?
Adolescent
4
2020
2079
0.260
Why?
Benzofurans
3
2020
6
0.260
Why?
Graft Rejection
2
2018
63
0.250
Why?
Valine
4
2019
6
0.240
Why?
Drug Interactions
2
2015
35
0.230
Why?
Incidence
2
2020
716
0.230
Why?
Cost-Benefit Analysis
4
2021
126
0.230
Why?
Risk Assessment
3
2018
629
0.230
Why?
Prospective Studies
4
2019
1668
0.220
Why?
Pyrrolidines
3
2018
11
0.220
Why?
Hepatitis Delta Virus
1
2023
1
0.220
Why?
Hepatitis B virus
1
2023
2
0.220
Why?
Hepatitis B Surface Antigens
1
2023
6
0.220
Why?
Amides
2
2020
16
0.220
Why?
Benzamides
1
2023
15
0.210
Why?
Vaccination
1
2023
29
0.210
Why?
Ritonavir
3
2019
3
0.210
Why?
Uracil
3
2019
4
0.210
Why?
Chronic Disease
3
2020
419
0.210
Why?
Mastocytosis, Systemic
1
2022
6
0.210
Why?
Chemoembolization, Therapeutic
1
2022
4
0.210
Why?
RNA
1
2022
33
0.210
Why?
Fibrosis
1
2022
26
0.200
Why?
History, 20th Century
1
2022
45
0.200
Why?
Aged, 80 and over
8
2020
4675
0.200
Why?
Selection Bias
1
2021
7
0.200
Why?
Graft Survival
2
2019
90
0.190
Why?
Fertility
1
2021
17
0.190
Why?
Aminoisobutyric Acids
2
2018
2
0.190
Why?
Leucine
2
2018
11
0.190
Why?
World Health Organization
1
2020
11
0.180
Why?
Tissue Donors
1
2021
72
0.180
Why?
End Stage Liver Disease
1
2020
10
0.180
Why?
Attitude of Health Personnel
1
2021
127
0.180
Why?
Critical Care
1
2022
190
0.180
Why?
Pandemics
1
2022
238
0.180
Why?
Anilides
2
2019
6
0.180
Why?
2-Naphthylamine
2
2019
3
0.180
Why?
Recurrence
2
2011
314
0.170
Why?
Hemorrhage
1
2020
78
0.170
Why?
Consensus
2
2021
83
0.170
Why?
Forecasting
1
2019
89
0.170
Why?
Drug and Narcotic Control
2
2016
3
0.170
Why?
Hyperemesis Gravidarum
1
2019
1
0.160
Why?
United States Food and Drug Administration
2
2016
22
0.160
Why?
Biomedical Research
1
2019
60
0.160
Why?
Practice Guidelines as Topic
3
2021
294
0.160
Why?
Follow-Up Studies
4
2015
1738
0.160
Why?
Logistic Models
2
2010
365
0.160
Why?
Transplant Recipients
1
2018
21
0.150
Why?
Internationality
1
2018
24
0.150
Why?
Dose-Response Relationship, Drug
1
2018
315
0.150
Why?
Infant, Newborn
1
2019
593
0.140
Why?
Time Factors
3
2016
1382
0.140
Why?
Drug Substitution
1
2017
4
0.140
Why?
Critical Pathways
1
2017
21
0.140
Why?
Psychometrics
1
2018
227
0.140
Why?
Counterfeit Drugs
1
2016
1
0.140
Why?
Patient Participation
1
2017
49
0.140
Why?
Severity of Illness Index
1
2020
936
0.140
Why?
Drug Approval
1
2016
7
0.140
Why?
Commerce
1
2016
12
0.130
Why?
Quality Control
1
2016
27
0.130
Why?
Surveys and Questionnaires
1
2021
1074
0.130
Why?
Canada
1
2016
49
0.130
Why?
Safety
1
2016
39
0.130
Why?
Ascites
1
2016
4
0.130
Why?
Paracentesis
1
2016
4
0.130
Why?
Interferons
1
2016
8
0.130
Why?
Hospitalization
2
2016
294
0.130
Why?
Fraud
1
2016
21
0.130
Why?
Eclampsia
1
2016
1
0.130
Why?
HELLP Syndrome
1
2016
2
0.130
Why?
Pre-Eclampsia
1
2016
7
0.130
Why?
Hydrogen-Ion Concentration
1
2016
128
0.130
Why?
Diffusion of Innovation
1
2015
30
0.130
Why?
Directive Counseling
1
2015
13
0.130
Why?
Benchmarking
1
2015
35
0.130
Why?
Administration, Oral
1
2015
100
0.130
Why?
Benzazepines
1
2015
4
0.130
Why?
Isoquinolines
1
2015
11
0.130
Why?
Comorbidity
4
2018
475
0.120
Why?
Deficiency Diseases
1
2015
2
0.120
Why?
Kidney Failure, Chronic
1
2017
151
0.120
Why?
Indoles
1
2015
34
0.120
Why?
Liver Failure
1
2015
8
0.120
Why?
Treatment Failure
2
2017
149
0.120
Why?
Zinc
1
2015
35
0.120
Why?
Phenotype
1
2015
289
0.120
Why?
Randomized Controlled Trials as Topic
1
2016
311
0.120
Why?
Hospitalists
1
2014
5
0.120
Why?
Off-Label Use
1
2014
6
0.120
Why?
Multivariate Analysis
2
2015
305
0.110
Why?
Cooperative Behavior
1
2014
73
0.110
Why?
Health Care Costs
1
2014
66
0.110
Why?
Internship and Residency
1
2016
206
0.110
Why?
Drug Eruptions
1
2013
9
0.110
Why?
Hematologic Diseases
1
2013
11
0.110
Why?
Viral Nonstructural Proteins
3
2017
4
0.100
Why?
Quality of Health Care
1
2014
121
0.100
Why?
Gastrointestinal Diseases
1
2013
35
0.100
Why?
Monitoring, Immunologic
1
2012
1
0.100
Why?
Drug Combinations
3
2017
33
0.100
Why?
Predictive Value of Tests
2
2017
459
0.100
Why?
CD4-Positive T-Lymphocytes
1
2012
108
0.090
Why?
Drug Carriers
1
2010
6
0.090
Why?
Quality-Adjusted Life Years
2
2021
20
0.090
Why?
Polymerase Chain Reaction
1
2010
106
0.090
Why?
Models, Statistical
1
2011
122
0.090
Why?
Odds Ratio
1
2010
265
0.090
Why?
Sensitivity and Specificity
1
2011
485
0.080
Why?
Fluorenes
2
2019
2
0.080
Why?
Clinical Trials as Topic
1
2009
215
0.080
Why?
Hemoglobins
1
2008
74
0.070
Why?
Cross-Sectional Studies
2
2021
853
0.070
Why?
Hospital Costs
2
2016
65
0.060
Why?
Carbonic Anhydrase IX
1
2022
1
0.050
Why?
Epithelial Cell Adhesion Molecule
1
2022
1
0.050
Why?
Neoplasm, Residual
1
2022
7
0.050
Why?
Pyrroles
1
2022
22
0.050
Why?
Hypoxia
1
2022
34
0.050
Why?
Pregnant Women
1
2021
10
0.050
Why?
Pyrazoles
1
2022
55
0.050
Why?
Waiting Lists
1
2019
14
0.040
Why?
Tissue and Organ Procurement
1
2019
29
0.040
Why?
Infection Control
1
2021
163
0.040
Why?
Insurance, Major Medical
1
2018
1
0.040
Why?
International Normalized Ratio
1
2018
19
0.040
Why?
Registries
1
2019
177
0.040
Why?
High-Throughput Nucleotide Sequencing
1
2017
44
0.040
Why?
Quality of Life
1
2022
621
0.040
Why?
Genetic Variation
1
2017
96
0.040
Why?
Uridine Monophosphate
1
2017
1
0.040
Why?
Decision Support Techniques
1
2017
48
0.030
Why?
Delivery of Health Care, Integrated
1
2017
24
0.030
Why?
Mental Disorders
1
2018
126
0.030
Why?
Serine Proteases
1
2016
6
0.030
Why?
Internal Medicine
1
2016
29
0.030
Why?
Career Choice
1
2016
29
0.030
Why?
Patient-Centered Care
1
2017
53
0.030
Why?
Pain Management
1
2018
137
0.030
Why?
Cost Savings
1
2016
30
0.030
Why?
Quality Indicators, Health Care
1
2016
36
0.030
Why?
Reproducibility of Results
1
2018
677
0.030
Why?
Patient Care Team
1
2017
132
0.030
Why?
Hospital Mortality
1
2016
136
0.030
Why?
Curriculum
1
2016
140
0.030
Why?
Statistics, Nonparametric
1
2015
117
0.030
Why?
Early Diagnosis
1
2015
65
0.030
Why?
Kaplan-Meier Estimate
1
2015
162
0.030
Why?
Databases, Factual
1
2016
333
0.030
Why?
Clinical Competence
1
2016
210
0.030
Why?
Linear Models
1
2015
239
0.030
Why?
Drug Industry
1
2014
6
0.030
Why?
Survival Rate
1
2015
322
0.030
Why?
Guideline Adherence
1
2014
60
0.030
Why?
Acquired Immunodeficiency Syndrome
1
2014
45
0.030
Why?
Inpatients
1
2014
135
0.030
Why?
Disease Progression
1
2015
687
0.030
Why?
Immunity, Cellular
1
2012
29
0.030
Why?
Immunoassay
1
2012
37
0.020
Why?
Probability
1
2012
85
0.020
Why?
Immunosuppressive Agents
1
2012
124
0.020
Why?
Postoperative Complications
1
2012
868
0.020
Why?
Reau's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (260)
Explore
_
Co-Authors (6)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_